RxDoctor Payments Data

Anshu Varma, MD

Internal Medicine · Fresno, CANPI 1275645558

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 41 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dynavax Technologies Corporation$167
  • Boehringer Ingelheim$163
  • United Therapeutics Corporation$116
  • Abiomed$97
  • Abbott$68
  • Dexcom, Inc.$65
  • plus $459 from 14 others

What the payments were for

  • Food & beverage$1,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$62,003
Medicare patients
88
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$33,916
EliquisApixaban20$17,148
OzempicSemaglutide14$14,795
JardianceEmpagliflozin11$14,172
JanuviaSitagliptin Phosphate15$13,528
Albuterol Sulfate HfaAlbuterol Sulfate38$1,774
ValacyclovirValacyclovir Hcl15$1,432
Trazodone Hcl28$1,210
Pantoprazole Sodium33$940
Gabapentin57$934
Duloxetine Hcl24$852
Atorvastatin Calcium93$792
Levothyroxine Sodium49$697
Lisinopril69$568
Losartan Potassium49$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$17,14820 claims
Novo NordiskOzempic$54$14,79514 claims
Boehringer IngelheimJardiance$163$14,17211 claims
MerckJanuvia$18$13,52815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →